Cargando…

Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers

Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geria...

Descripción completa

Detalles Bibliográficos
Autores principales: Safcak, Dominik, Drazilova, Sylvia, Gazda, Jakub, Andrasina, Igor, Adamcova-Selcanova, Svetlana, Balazova, Lea, Barila, Radovan, Mego, Michal, Rac, Marek, Skladany, Lubomir, Zigrai, Miroslav, Janicko, Martin, Jarcuska, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318669/
https://www.ncbi.nlm.nih.gov/pubmed/35887947
http://dx.doi.org/10.3390/jcm11144183
_version_ 1784755350132490240
author Safcak, Dominik
Drazilova, Sylvia
Gazda, Jakub
Andrasina, Igor
Adamcova-Selcanova, Svetlana
Balazova, Lea
Barila, Radovan
Mego, Michal
Rac, Marek
Skladany, Lubomir
Zigrai, Miroslav
Janicko, Martin
Jarcuska, Peter
author_facet Safcak, Dominik
Drazilova, Sylvia
Gazda, Jakub
Andrasina, Igor
Adamcova-Selcanova, Svetlana
Balazova, Lea
Barila, Radovan
Mego, Michal
Rac, Marek
Skladany, Lubomir
Zigrai, Miroslav
Janicko, Martin
Jarcuska, Peter
author_sort Safcak, Dominik
collection PubMed
description Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (p = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (p = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (p = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (p = 0.5), one and two comorbidities (p = 0.49), and three or more comorbidities (p = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted.
format Online
Article
Text
id pubmed-9318669
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93186692022-07-27 Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers Safcak, Dominik Drazilova, Sylvia Gazda, Jakub Andrasina, Igor Adamcova-Selcanova, Svetlana Balazova, Lea Barila, Radovan Mego, Michal Rac, Marek Skladany, Lubomir Zigrai, Miroslav Janicko, Martin Jarcuska, Peter J Clin Med Article Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (p = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (p = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (p = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (p = 0.5), one and two comorbidities (p = 0.49), and three or more comorbidities (p = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted. MDPI 2022-07-19 /pmc/articles/PMC9318669/ /pubmed/35887947 http://dx.doi.org/10.3390/jcm11144183 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Safcak, Dominik
Drazilova, Sylvia
Gazda, Jakub
Andrasina, Igor
Adamcova-Selcanova, Svetlana
Balazova, Lea
Barila, Radovan
Mego, Michal
Rac, Marek
Skladany, Lubomir
Zigrai, Miroslav
Janicko, Martin
Jarcuska, Peter
Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title_full Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title_fullStr Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title_full_unstemmed Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title_short Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
title_sort inflammatory indexes as prognostic factors of survival in geriatric patients with hepatocellular carcinoma: a case control study of eight slovak centers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318669/
https://www.ncbi.nlm.nih.gov/pubmed/35887947
http://dx.doi.org/10.3390/jcm11144183
work_keys_str_mv AT safcakdominik inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT drazilovasylvia inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT gazdajakub inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT andrasinaigor inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT adamcovaselcanovasvetlana inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT balazovalea inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT barilaradovan inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT megomichal inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT racmarek inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT skladanylubomir inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT zigraimiroslav inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT janickomartin inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters
AT jarcuskapeter inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters